Document Detail


Fetal neurobehavioral effects of exposure to methadone or buprenorphine.
MedLine Citation:
PMID:  20868741     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
As part of a double-blind study of medication treatment for opioid dependence during pregnancy, 17 opioid-dependent pregnant women maintained on either buprenorphine or methadone underwent fetal monitoring at 24, 28, 32, and 36 weeks gestation. Maternal demographic information and infant outcomes did not significantly differ by medication group. Earlier in gestation (24 and 28 weeks), buprenorphine-exposed fetuses had higher levels of fetal heart rate variability, more accelerations in fetal heart rate and greater coupling between fetal heart rate and fetal movement than the methadone-exposed group (all ps < .05). Later in gestation (32 and 36 weeks), buprenorphine-exposed fetuses displayed less suppression of motor activity and longer duration of movements than the methadone-exposed group (all ps < .05). These results may have implications for the optimal treatment of the opioid-dependent pregnant woman.
Authors:
Lauren M Jansson; Janet A Dipietro; Martha Velez; Andrea Elko; Erica Williams; Lorraine Milio; Kevin O'Grady; Hendrée E Jones
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2010-09-22
Journal Detail:
Title:  Neurotoxicology and teratology     Volume:  33     ISSN:  1872-9738     ISO Abbreviation:  Neurotoxicol Teratol     Publication Date:    2011 Mar-Apr
Date Detail:
Created Date:  2011-04-06     Completed Date:  2011-07-22     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  8709538     Medline TA:  Neurotoxicol Teratol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  240-3     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Behavior / drug effects,  physiology
Buprenorphine / administration & dosage,  adverse effects*,  therapeutic use
Double-Blind Method
Female
Fetal Monitoring
Fetal Movement / drug effects
Fetus / drug effects*,  physiopathology
Gestational Age
Heart Rate, Fetal / drug effects,  physiology
Humans
Methadone / administration & dosage,  adverse effects*,  therapeutic use
Opiate Substitution Treatment*
Opioid-Related Disorders / physiopathology*,  rehabilitation
Pregnancy
Pregnancy Complications / physiopathology*,  rehabilitation
Young Adult
Grant Support
ID/Acronym/Agency:
R01 DA015764/DA/NIDA NIH HHS; R01 DA015764/DA/NIDA NIH HHS; R01 DA015764-05/DA/NIDA NIH HHS; R01 DA019934/DA/NIDA NIH HHS; R01 DA019934/DA/NIDA NIH HHS; R01 DA019934-05/DA/NIDA NIH HHS; R01 HD027592/HD/NICHD NIH HHS; R01 HD027592-20/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
40D3SCR4GZ/Buprenorphine; UC6VBE7V1Z/Methadone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Maternal diet modulates the risk for neural tube defects in a mouse model of diabetic pregnancy.
Next Document:  Prenatal exposure to lead and cognitive deficit in 7- and 14-year-old children in the presence of co...